The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Vol.
42
No.
37
October 07, 2016Oct 07, 2016
Free
DOWNLOAD THE PDF
With 20 Agents, 803 Trials, and 166,736 Patient Slots, Is Pharma Investing Too Heavily in PD-1 Drug Development?
Cover Story
Free

With 20 Agents, 803 Trials, and 166,736 Patient Slots, Is Pharma Investing Too Heavily in PD-1 Drug Development?

By Laura Brawley
Pharmaceutical companies are betting big on cancer immunotherapies that rely on the PD-1 protein and its ligands, PD-L1 and PD-L2, to initiate an immune response.
Perspectives on Clinical Development of PD-1 Drugs
Conversation with The Cancer LetterFree

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account